NEWAMSTERDAM PHARMA CO NV (NAMS) Stock News
NASDAQ:NAMS - Nasdaq - NL00150012L7 - Common Stock - Currency: USD
NAMS Latest News, Press Relases and Analysis
NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors
NAARDEN, the Netherlands and MIAMI, April 17, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the...
NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors
NewAmsterdam Pharma (NAMS): Among Billionaire Stanley Druckenmiller’s Top Stock Picks with Huge Upside Potential
We recently published a list of Billionaire Stanley Druckenmiller’s Top 10 Stocks Picks with Huge Upside Potential. In this article, we are going to take a look at where NewAmsterdam Pharma Company N.V (NASDAQ:NAMS) stands against other Billionaire Stanley Druckenmiller’s other top stock picks with huge upside potential. Wall Street is overflowing with data. If […]
Nissan sells its Indian plant to Renault to raise cash
Sale is part of broader restructuring of the Alliance.
Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?
The company unveiled promising results for its experimental cholesterol treatment, a daily pill that blocks PCSK9.
NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference
NAARDEN, the Netherlands and MIAMI, March 31, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the...
NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference
NewAmsterdam Pharma Stock Hits 90-Plus RS Rating
NewAmsterdam Pharma stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 74 to 95.
NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update
-- EMA submission expected in 2H25 by partner Menarini -- -- Additional data from BROADWAY, BROOKLYN, and TANDEM to be presented throughout 2025 -- ...
NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March
NAARDEN, The Netherlands and MIAMI, Feb. 25, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”),...
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAARDEN, the Netherlands and MIAMI, Feb. 07, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”),...
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference
NAARDEN, The Netherlands and MIAMI, Jan. 29, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”),...
NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference
NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAARDEN, the Netherlands and MIAMI, Jan. 09, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a...
Menarini Group gibt positive Topline-Daten aus den klinischen Phase-3-Studien BROADWAY und TANDEM zur Bewertung von Obicetrapib und der Fixkombination Obicetrapib mit Ezetimib 10 mg bekannt
- Beide entscheidenden Studien erreichten die primären Endpunkte der mittleren Senkung des LDL-Cholesterins zusätzlich zu maximal verträglichen lipidsenkenden...
Menarini Group annonce des données de base positives issues des essais cliniques pivots de phase 3 BROADWAY et TANDEM qui évaluent l'Obicetrapib et l'association à dose fixe d'Obicetrapib et d'Ézétimibe 10 mg
– Les deux études pivot s ont atteint les critères d'évaluation primaires de réduction moyenne par les moindres carrés (LS) du LDL-C en plus des thérapies de...
Menarini Group anuncia datos positivos de los ensayos clínicos fundamentales de fase 3 BROADWAY y TANDEM
– Menarini Group anuncia datos positivos de los ensayos clínicos fundamentales de fase 3 BROADWAY y TANDEM que evalúan obicetrapib y la combinación de dosis...
Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg
– Both pivotal studies achieved primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies with high statistical...
NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
NAARDEN, The Netherlands and MIAMI, Dec. 13, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a...
NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
NAARDEN, the Netherlands and MIAMI, Dec. 11, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a...